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Introduction: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an 
increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an 
increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related 
risk in patients with hematological neoplasms remains unclear. We, therefore, aimed to assess 
the ESA-related risk of VTE, myocardial infarction (MI), and stroke in patients with multiple 
myeloma (MM) and myelodysplastic syndrome (MDS).
Materials and methods: We conducted a population-based cohort study in Denmark, 
using medical databases to identify 2,114 MDS patients and 3,105 MM patients diagnosed in 
2004–2013. Incidence rates per 1,000 person-years and hazard ratios (HRs) with 95% confidence 
intervals (CIs) for VTE, MI, and stroke associated with ESA treatment were computed. HRs 
were calculated in time-dependent Cox regression and adjusted for age, sex, MDS prognosis 
group, comorbidities, and treatments.
Results: Incidence rates per 1,000 person-years for VTE, MI, and stroke were 10.8, 8.2, and 
16.0 in MDS patients, and 21.9, 10.2 and 9.9 in MM patients without ESA treatment, respec-
tively. MDS patients with ESA treatment had a 1.6-fold increased risk of MI (HR 1.60 [95% 
CI 0.90–2.86]) and an almost twofold increased risk of stroke (HR 1.94 [95% CI 1.28–2.94]). 
Adjusted HR for VTE was 1.04 (95% CI 0.57–1.89) compared with MDS patients without ESAs. 
In MM patients with ESAs compared with patients without ESAs, HRs were 1.41 (95% CI 
0.96–2.08) for VTE, 1.23 (95% CI 0.68–2.20) for MI, and 1.63 (95% CI 0.96–2.77) for stroke.
Conclusion: ESA use was associated with stroke in MDS patients. Among MM patients, 
ESA treatment was associated with a higher risk of all cardiovascular events, although all CIs 
included equivalence.
Keywords: cohort study, epidemiology, erythropoietin, multiple myeloma, myelodysplastic 
syndromes, myocardial infarction, stroke, pulmonary embolism, venous thrombosis
Introduction
Erythropoiesis-stimulating agents (ESAs) are used to treat anemia, in order to reduce 
the need for red blood cell transfusions. After ESAs first proved successful in treat-
ing anemia in patients with chronic kidney disease, ESAs were also implemented in 
the treatment of anemia associated with malignancies.1 In the past decade, several 
meta-analyses, including trials of patients with mainly solid tumors, have reported an 
up to 1.17-fold increased mortality risk associated with ESA treatment.2–4 Also, an 
increased risk of venous thromboembolism (VTE) has been reported in cancer patients 
treated with ESAs.5 Concurrently, higher doses of ESAs and higher hemoglobin tar-
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gets have also been associated with increased mortality and 
cardiovascular risk in patients with non-malignant chronic 
kidney disease.6
As a consequence, ESA treatment in patients with solid 
tumors is now restricted to certain patients with chemother-
apy-induced anemia.1,7 However, ESA treatment is widely 
used in patients with the hematological neoplasms myelo-
dysplastic syndrome (MDS) and multiple myeloma (MM). 
MDS patients generally are believed to be at low risk of VTE, 
mainly because of the high incidence of thrombocytopenia 
and anemia8 and a previous case-crossover study reported no 
increased risk of VTE in MDS patients treated with ESAs.9 
However, an earlier Phase II trial in low-to-intermediate 
risk MDS patients was halted early because three out of 
seven patients developed a VTE.10 Also, a higher incidence 
of VTE with ESA treatment in patients with MM has been 
reported.11,12
The hemato-oncology literature has concentrated mainly 
on the effect of ESAs on VTE events.13 An effect of ESAs on 
cardiovascular events, as described in patients with chronic 
kidney disease, is infrequently reported. A meta-analysis 
showed a 1.7-fold increased risk of a combination of venous 
and arterial thrombotic events in ESA-treated patients, mainly 
with solid tumors, compared with cancer patients who did not 
receive ESA treatment.4 It is difficult to deduce the contribu-
tion of myocardial infarction (MI), and stroke. No increased 
risk of combined arterial and venous thrombotic events 
with ESA treatment was reported in an earlier study of MM 
patients.14 In the current study, we therefore aimed to examine 
the association between ESA use and cardiovascular events 
in patients with MM and MDS in a large population-based 
cohort study. To that end, we calculated the ESA-related risk 
of VTE, MI, and stroke separately.
Methods
We conducted a population-based cohort study in Denmark, 
linking individual-level records among different Danish reg-
istries using the civil personal register (CPR) number.15,16 This 
unique and permanent identification number is assigned to all 
Danish residents alive on, or born after 1968 or at the time 
of immigration. In Denmark, the National Health Service 
provides universal tax-supported health care, guaranteeing 
unfettered access to general practitioners and hospitals.
Data sources
The Danish Cancer Registry (DCR) contains records of all 
incident cases of malignant neoplasms in Denmark since 
1943 and provides details on histology, morphology, and 
cancer stage at diagnosis.17 Throughout our study period, 
tumors were classified according to the tenth revision of the 
International Classification of Diseases (ICD-10).
The Danish National Patient Registry (DNPR) provides 
information on all non-psychiatric hospital inpatient admis-
sions since 1977 and on all outpatient clinic and emergency 
room visits since 1995.18 Each inpatient hospital discharge or 
outpatient visit is recorded with one primary diagnosis and 
up to 19 secondary diagnoses classified according to ICD-8 
through 1993 and ICD-10 thereafter. Surgical and treatment 
information is coded according to a Danish classification 
(1977 through 1995) and a Danish version of the Nordic 
Medico-Statistical Committee (NOMESCO) Classification 
of Surgical Procedures (from 1996 on).
The National Health Service Prescription Database 
(NHSPD) includes information on reimbursed prescriptions 
redeemed at community and outpatient pharmacies since 
January 1, 2004.19 Each time a prescription is redeemed at a 
pharmacy, the date, the types, and quantity of the prescribed 
drug (according to the Anatomical Therapeutic Chemical 
Classification System [ATC]) is transmitted to the database.
The Danish Civil Registration System (CRS), established 
in 1968, contains information on gender, residence and date 
of death and emigration, with daily updates.16
study cohort
The study included all adult patients (age ≥18 years) with a 
first-time diagnosis of MDS or MM in the DCR during the 
period July 1, 2004–December 31, 2013 (codes in Table S1). 
Non-Danish born patients were excluded due to possible 
incomplete data on comorbidities (see Figure 1). MDS was 
in this study categorized as “standard prognosis,” “poor prog-
nosis,” and “other”, based solely on the ICD-10 diagnoses 
(codes in Table S1).
Exposure
ESA treatment was defined as a time-dependent exposure 
according to data in the DNPR (codes in Table S1). Start 
of ESA treatment was defined as the first date on which 
the specific ESA treatment code appeared (Table S1). 
Generally, MDS and MM patients would be provided with 
free-of-charge ESAs from the hospital departments that 
treat their diseases. However, in order to investigate if any 
patients were prescribed ESA treatment through commu-
nity pharmacies, we also performed a cross-check with the 
NHSPD (codes in Table S1). The cross-check did not yield 
additional patients who were treated with ESAs. Patients 
and person-years were considered unexposed before starting 
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ESA treatment and exposed from start of ESA treatment 
until end of follow-up.
Covariates
Sex and age were extracted from CRS. Diabetes mellitus, 
chronic kidney disease, and cardiovascular disease were iden-
tified from the DNPR. In order to increase the sensitivity of 
diagnoses of diabetes mellitus, and cardiovascular diseases, 
we also searched the NHSPD for any previous dispensing 
of diabetic medication and medication of cardiovascular 
diseases. Statin use was also obtained from the NHSPD. 
Antithrombotic therapy was also identified from the NHSPD 
and checked with a treatment code from the DNPR. Anti-
thrombotic therapy was defined as vitamin K antagonists, 
platelet aggregation inhibitors, and others (ie, heparins, direct 
thrombin inhibitors, direct factor Xa inhibitors). VTE prophy-
laxes in MM patients was with platelet aggregation inhibitors 
during and shortly after treatment with immunomodulating 
therapy, or with low molecular weight heparin if there is a 
history of venous thrombosis or other risk factors. Data on 
chemotherapy, treatment with azacitidine, thalidomide or 
lenalidomide, any other immunomodulating or bone modu-
lating therapy and radiation therapy were obtained from the 
DNPR (all codes and definitions are provided in Table S1). 
Pomalidomide was not in clinical use during the study period.
Follow-up and outcomes
The DNPR was also used to identify the outcomes of inter-
est: VTE, MI, and stroke. Patients diagnosed with VTE, MI, 
or stroke only in the emergency room setting were excluded 
from the analysis, due to the expected low positive predictive 
value of the working diagnoses. For each analyzed event, 
patients who were diagnosed with that specific event before 
start of follow-up were excluded from the analyses. For the 
primary analysis, follow-up started on the MDS or MM 
diagnosis date. Patients were followed until the first date of 
the specific outcome, emigration, death, or end of follow-up 
on December 31, 2014, whichever came first. Mortality data 
were obtained from the CRS.16
statistical analyses
Baseline characteristics were stratified for MDS and MM 
patients with and without ESA treatment. Age was expressed 
as median with interquartile range, and categorical data 
as percentages. Rates of VTE, MI, and stroke were cal-
culated and expressed as the number of events per 1,000 
person-years. Time-dependent Cox regression analysis was 
performed to compute crude and adjusted hazard ratios 
(HRs) with 95% confidence intervals (CIs). Analyses were 
adjusted for sex, age, MDS risk group (only for analyses 
including MDS patients), diabetes mellitus, chronic kidney 
disease, cardiovascular disease, statin, and antithrombotic 
agent use at baseline. Additional adjustment (adjust-
ment b) was made for time-updated concurrent treatments: 
chemotherapy, azacitidine, thalidomide or lenalidomide, 
 immunomodulating therapy, and radiation therapy. In addi-
tion, we included use of Filgrastim and/or thrombopoietin 
analogs in regression models adjusting for time-dependent 
concurrent treatments (all codes and definitions are provided 
in Table S1).
Three sensitivity analyses were performed to check the 
robustness of our results. First, as ESA treatment is most often 
Identified patients with MDS 
and MM between 2004 and 2013 
N = 5,533
Final study population
N = 5,219
Excluded:
n=261
n=22
n=31
- non-Danish born
- wrong diagnosis code
- age ≤ 18 years
Figure 1 Flow chart of study population.
Abbreviations: MM, multiple myeloma, MDs, myelodysplastic syndrome.
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started shortly after diagnosis, and the duration of ESAs’ 
effect is under debate, we did a sensitivity analysis where 
follow-up was restricted to the first 2 years following MDS or 
MM diagnosis. The second sensitivity analysis was restricted 
to patients receiving chemotherapy, since this would create 
a more homogeneous group of patients. In this sensitivity 
analysis, follow-up was started on the date of chemotherapy 
initiation. Furthermore, in order to address a potential effect 
of patients in current anti-myeloma treatment we did a sen-
sitivity analysis excluding patients without chemotherapy or 
immunomodulating treatment.
All analyses were performed with SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA). The study was approved 
by the Danish Data Protection Agency (record number 
2011-41-5755).
Results
Descriptive characteristics of the study 
population
In total, 2,114 patients with MDS and 3,105 patients with 
MM were identified. Baseline characteristics are shown in 
Table 1. Slightly more patients in both groups were male 
and median age was 76 years in MDS patients and 71 years 
in MM patients. ESA-treated patients were more likely to 
have a previous diagnosis of cardiovascular disease, diabetes 
mellitus, or chronic kidney disease. Antithrombotic agent 
use at baseline was similar in patients with and without ESA 
treatment. As expected, most MM patients were treated with 
chemotherapy during follow-up.
incidence rates overall and in subjects 
without Esa treatment
Table 2 displays the number of events and incidence rates 
of VTE, MI, and stroke per 1,000 person-years. In MDS 
patients, a total of 54 VTEs, 52 MIs, and 101 strokes were 
observed in at least 5,036 person-years of follow-up, depend-
ing on the event of interest. For MM patients, the total 
number of person years was at least 8,602, and 195 VTEs, 
92 MIs, and 93 strokes were observed. The incidence rate 
of VTE was 10.8 per 1,000 person-years in MDS patients 
without ESA treatment and twice as high in MM patients 
without ESA treatment, at 21.9 per 1,000 person-years. The 
Table 1 Baseline characteristics of patients with MDs and MM at diagnosis (between July 1, 2004 and December 31, 2013) by Esa 
during follow-up
Covariates MDS MM
No ESA
(N=1,212)
ESA
(N=902)
No ESA
(N=2,405)
ESA
(N=700)
agea 75.4 (65.1–81.9) 76.2 (68.9–82.4) 70.6 (63.1–78.6) 71.7 (64.0–78.5)
Male 57.6 59.4 55.4 56.0
Cardiovascular disease 72.8 76.8 69.1 71.6
hypertensive disease 25.4 24.9 24.7 25.6
ischemic heart disease 20.6 21.7 14.1 18.4
heart failure 11.1 9.3 6.2 6.4
Diabetes mellitus 13.8 17.5 10.4 11.9
Chronic kidney disease 5.0 6.0 9.4 14.4
statin use 24.7 29.7 25.9 30.9
antithrombotic agents 42.7 47.1 35.6 36.1
Vitamin K antagonist 10.8 11.3 9.7 7.3
Platelet inhibitors 37.5 41.9 29.8 32.3
MDs groups
standard prognosis 20.0 26.7 – –
Poor prognosis 15.5 15.0 – –
Other 64.5 58.3 – –
Chemotherapy during FU 27.8 32.9 70.9 95.7
radiation therapy during FU 7.8 7.6 27.4 25.4
immunomodulating drugs during FU 6.0 16.2 65.3 92.7
Filgrastim and/or thrombopoietin analogs during FU 8.8 43.2 27.6 54.1
Years to Esa during FUa – 0.24 (0.08–0.84) – 0.82 (0.23–2.52)
Notes: Values are presented as percentages or amedian (interquartile range).
Abbreviations: MDs, myelodysplastic syndrome; Esa, erythropoiesis-stimulating agent during follow-up; FU, follow-up; MM, multiple myeloma.
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incidence rate of stroke was higher in MDS patients than in 
MM patients, with 16.0 per 1,000 person-years and 9.9 per 
1,000 person-years in MDS and MM patients without ESA 
treatment, respectively.
Esa-treated patients
As displayed in Table 2, crude incidence rates of MI and 
stroke were higher in ESA-treated patients compared with 
patients without ESA treatment. The crude and adjusted HRs 
for VTE, MI, and stroke during the total follow-up period 
are shown in Table 3. While the fully adjusted HR of VTE 
for ESA-treated MDS patients compared to MDS patients 
without ESA treatment was 1.04 (95% CI 0.57–1.89), 
ESA-treated MDS patients had a 1.6-fold increased risk of 
MI (HR 1.60 [95% CI 0.90–2.86]) and an almost twofold 
increased risk of stroke (HR 1.94 [95% CI 1.28–2.94]). 
Among MM patients, ESA treatment was associated with 
a higher risk of all cardiovascular events, although all CIs 
included equivalence. Fully adjusted HRs were 1.41 (95% 
CI 0.96–2.08) for VTE, 1.23 (95% CI 0.68–2.20) for MI, 
and 1.63 (95% CI 0.96–2.77) for stroke. Overall, additional 
adjustment for time-updated concurrent treatments (adjust-
ment b) affected estimates only minimally. The results were 
only marginally different after inclusion of Filgrastim and/
or thrombopoietin analogs in the fully adjusted regression 
models (data not shown).
sensitivity an alyses
When the analyses were restricted to 2 years of follow-up, 
results for MDS patients were in line with the main results 
(Table 4). In MM patients, the results were also similar. 
Although the association between ESA treatment and VTE 
and MI became somewhat more pronounced, CIs were wide. 
When we repeated the analyses in the cohort of MDS patients 
treated with chemotherapy (Table 5), the association of ESA 
treatment with MI and stroke attenuated. In MM patients, 
the results were in line with the main analysis. The HR for 
stroke in ESA-treated MM patients with chemotherapy was 
1.68 (95% CI 0.95–2.98). Exclusion of patients without 
chemotherapy or immunomodulating treatment from the 
MM cohort resulted in only marginal changes in the crude 
and adjusted HRs (data not shown).
Discussion
Our population-based cohort study showed an elevated risk of 
cardiovascular events in ESA-treated MM patients. In MDS 
Table 2 incidence rates of VTE, Mi, and stroke per 1,000 person-years
Outcome ESA Myelodysplastic syndrome Multiple myeloma
Events Person- years IR (95% CI) Events Person-years IR (95% CI)
VTE Yes 18 1,923 9.4 (5.0–13.7) 36 1,333 27.0 (18.2–35.8)
no 36 3,329 10.8 (7.3–14.4) 159 7,269 21.9 (18.5–25.3)
MI Yes 25 1,854 13.5 (8.2–18.8) 16 1,348 11.9 (6.1–17.7)
no 27 3,309 8.2 (5.1–11.2) 76 7,450 10.2 (7.9–12.5)
Stroke Yes 50 1,845 27.1 (19.6–34.6) 21 1,389 15.1 (8.7–21.6)
no 51 3,191 16.0 (11.6–20.4) 72 7,302 9.9 (7.6–12.1)
Abbreviations: ir, incidence rate (per 1,000 person-years at risk); VTE, venous thromboembolism; Mi, myocardial infarction; Esa, erythropoiesis-stimulating agent.
Table 3 hrs for Esa-treated patients compared with patients not treated with Esa during complete follow-up
Outcome MDS Multiple myeloma
Crude HR 
(95% CI)
Adjusted HRa  
(95% CI)
Adjusted HRb  
(95% CI)
Crude HR 
(95% CI)
Adjusted HRa 
(95% CI)
Adjusted HRb 
(95% CI)
VTE 0.96 (0.53–1.72) 0.98 (0.54–1.77) 1.04 (0.57–1.89) 1.66 (1.14–2.43) 1.70 (1.16–2.49) 1.41 (0.96–2.08)
MI 1.86 (1.06–3.27) 1.57 (0.89–2.79) 1.60 (0.90–2.86) 1.48 (0.85–2.59) 1.25 (0.70–2.20) 1.23 (0.68–2.20)
Stroke 1.99 (1.33–2.98) 1.94 (1.29–2.93) 1.94 (1.28–2.94) 1.83 (1.11–3.03) 1.58 (0.94–2.65) 1.63 (0.96–2.77)
Notes: aadjusted for sex, age, diabetes mellitus, MDs prognosis group (in case of MDs), chronic kidney disease, cardiovascular disease, statin use, and antithrombotic therapy 
at baseline. badditionally adjusted for chemotherapy, radiotherapy, immunomodulating therapy, and antithrombotic therapy as time-dependent covariates.
Abbreviations: MDs, myelodysplastic syndrome; hr, hazard ratio; VTE, venous thromboembolism; Mi, myocardial infarction; Esa, erythropoiesis-stimulating agent.
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patients, ESA use was also associated with cardiovascular 
events, mainly with stroke and MI.
In patients with MM, the overall incidence rate of VTE 
was high, ie, 22.67 per 1,000 person-years, which is about 
tenfold higher than in the general population. Previous 
studies have reported a VTE frequency ranging from 2% 
up to 28% in MM patients during treatment with different 
regimens including thalidomide, in varying timeframes up 
to two years,11,20 suggesting that the risk seems to depend on 
concurrent treatments. Especially use of the immunomodula-
tory agents thalidomide, lenalidomide, and dexamethasone 
has been associated with higher VTE risk.21,22 ESA use has 
also been reported as a risk factor for VTE in MM patients 
taking immunomodulating drugs and in newly diagnosed 
MM patients, with a relative risk up to 3.4.12,23 Furthermore, 
in MM patients taking lenalidomide and dexamethasone, 
concomitant ESA therapy increased the incidence from 5% 
to 23%.11 However, an earlier study in MM patients taking 
thalidomide did not show a relation between the occurrence 
of thrombosis and ESA treatment,14 and a pooled analyses 
of newly diagnosed MM patients enrolled in clinical trials in 
Italy and the United States showed no effect of ESA on the 
VTE rate.24 Our results, taking concomitant anticoagulant and 
immunomodulating therapy into account, indicated a 1.4-fold 
increase in VTE in ESA-treated MM patients.
Risk of VTE in MDS patients does not seem so much 
higher than that in the general population, but the contribu-
tion of ESAs or other treatments has been investigated infre-
quently. Available studies in MDS patients found that ESAs 
did not increase the VTE rate.25,26 The reported VTE rate for 
MDS patients receiving lenalidomide in a postmarketing sur-
veillance study was only 0.53%, but there were some signals 
of an association with ESA use.27 In line with our results, a 
later study found an odds ratio of 1.2 with ESA treatment and 
concluded that the safety profile of ESAs may be different 
in MDS patients than in patients with solid tumors.9 Still, 
an increased VTE rate has been reported in MDS patients 
receiving ESAs in combination with thalidomide.10
Little is known about the occurrence of MI and stroke in 
the two patient groups, especially in relation with ESA use. 
However, compared to an age-matched general population, 
MM patients have a 1.5 to 2-fold increased risk of arterial 
thrombosis.28 In our study, the incidence of MI in both MDS 
and MM without ESA treatment is in line with the upper limit 
of the incidence of the general population.29–31 The incidence 
of stroke in MM patients without ESA is also in line with 
the upper limit of the incidence in the general population, 
but in MDS patients without ESA the incidence of stroke is 
about two to three times higher compared with the general 
population.29,32 ESA treatment has been related to cardiovas-
Table 4 HRs for ESA-treated patients compared to patients not treated with ESAs during the first 2 years of follow-up
Outcome MDS Multiple myeloma
Crude HR 
(95% CI)
Adjusted HRa 
(95% CI)
Adjusted HRb 
(95% CI)
Crude HR 
(95% CI)
Adjusted HRa 
(95% CI)
Adjusted HRb 
(95% CI)
VTE 0.69 (0.29–1.64) 0.76 (0.32–1.83) 0.81 (0.34–1.95) 1.97 (1.23–3.15) 1.99 (1.24–3.21) 1.76 (1.09–2.85)
MI 1.85 (0.88–3.89) 1.60 (0.75–3.39) 1.59 (0.75–3.38) 1.85 (0.76–4.50) 1.47 (0.59–3.64) 1.47 (0.58–3.71)
Stroke 1.99 (1.22–3.23) 1.95 (1.19–3.20) 1.97 (1.19–3.24) 1.13 (0.44–2.92) 0.92 (0.35–2.40) 0.95 (0.36–2.53)
Notes: aadjusted for sex, age, diabetes mellitus, MDs prognosis group (in case of MDs), chronic kidney disease, cardiovascular disease, statin use, and antithrombotic therapy 
at baseline. badditionally adjusted for chemotherapy, radiotherapy, immunomodulating therapy, and antithrombotic therapy as time-dependent covariates.
Abbreviations: MDs, myelodysplastic syndrome; hr, hazard ratio; VTE, venous thromboembolism; Mi, myocardial infarction; Esa, erythropoiesis-stimulating agent.
Table 5 hrs for Esa-treated patients compared to patients not treated with Esas, with follow-up starting at initiation of chemotherapy
Outcome MDS Multiple myeloma
Crude HR (95% CI) Adjusted HRa (95% CI) Crude HR (95% CI) Adjusted HRa (95% CI)
VTE 0.58 (0.20–1.63) 0.71 (0.24–2.07) 1.48 (1.00–2.17) 1.47 (0.99–2.19)
MI 2.04 (0.45–9.13) 1.44 (0.28–7.34) 1.57 (0.84–2.92) 1.30 (0.68–2.48)
Stroke 1.42 (0.71–2.84) 1.52 (0.75–3.10) 1.96 (1.13–3.39) 1.68 (0.95–2.98)
Notes: aadjusted for sex, age, MDs risk group (in case of MDs), diabetes mellitus, chronic kidney disease, cardiovascular disease, statin use at baseline, time-updated 
antithrombotic therapy, and type of chemotherapy.
Abbreviations: MDs, myelodysplastic syndrome; hr, hazard ratio; VTE, venous thromboembolism; Mi, myocardial infarction; Esa, erythropoiesis-stimulating agent.
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cular events in general oncology patients and patients with 
chronic kidney disease. A meta-analysis reported a 1.67 (95% 
CI 1.35–2.06) increased risk of thromboembolic events (a 
composite of VTE, transient ischemic attack, stroke, and MI) 
in oncology patients treated with ESAs.4 Only a minority 
of the studies in this meta-analysis included MM or MDS 
patients, and these were mostly performed before 2002. In 
patients with chronic kidney disease, ESA use is related to 
a 1.15-fold increased risk of serious cardiovascular events, 
with a 1.51 fold increased risk of stroke.6 Our results also 
indicate a higher risk of stroke and MI with ESA use in both 
MDS and MM patients.
A number of mechanisms have been proposed for the 
increase in cardiovascular events with ESA therapy.33 The 
higher blood viscosity induced by ESAs could increase the 
risk of thrombotic events, but this is mainly reported for 
above-normal hematocrit levels, such as in patients with 
polycythemia vera.34 ESAs also have been associated with 
vasoconstriction, may activate vascular endothelium, and 
could increase blood pressure.35 In addition, ESAs have been 
associated with pro-thrombotic changes, including increased 
platelet counts, lower levels of protein C and S, and increased 
thrombin generation.36,37 ESA treatment probably augments 
the already increased risk of cardiovascular events in the two 
populations, due to inherent thrombosis risks of MDS and 
MM and shared risk factors. For instance, smoking increases 
the risk of both MDS and arterial thrombosis.38 Furthermore, 
MM increases the risk of VTE in itself, through fractures 
and surgeries and the aforementioned immunomodulating 
therapy.39
Our study is notable for the large number of patients 
identified from population-based registries covering the 
complete Danish population. Also, the accuracy of a number 
of ICD-10 codes and quality of VTE diagnosis in the DNPR 
have been validated, and the positive predictive value was 
found to be very high.40,41 Furthermore, any misclassifica-
tion would probably be non-differential and would lead 
to underestimation, since ICD-10 codes and diagnosis are 
unlikely to differ by ESA use. A concern is that the exact 
end date of ESA treatment and its effects are unknown. In 
our analyses, we assumed that patients were exposed from 
the start of ESA treatment until the end of follow-up. It is 
noteworthy that sensitivity analyses restricting follow-up to 
2 years yielded similar results.
The validity of our findings also depends on proper adjust-
ment for confounding. Our HRs were adjusted for an array of 
confounding factors, including comorbidities and concurrent 
therapies such as antithrombotic agents and immunomodulat-
ing drugs. However, as with all observational studies, residual 
confounding cannot be excluded.42 Unfortunately, we lacked 
detailed information on laboratory parameters, including Hb 
and platelet values. Since the decision for ESA treatment is 
based on Hb levels, symptoms of anemia, and transfusion 
dependency, therefore all ESA-treated patients are anemic, 
and the effects of Hb and ESA are always strongly associated. 
Since anemia is a risk factor for cardiovascular events or at 
least for MI, ESA-treated patients would have a higher risk 
of MI due to their anemia. This could lead to confounding 
by indication and an overestimation of the ESA effect. Also, 
because low-risk MDS patients are most often treated with 
ESAs in clinical practice, we also adjusted for type of MDS in 
our analyses. If we did assume that higher-risk MDS confers 
a higher risk of cardiovascular events, the HRs calculated in 
our study would likely underestimate the true ESA effect in 
the MDS patient group. On the other hand, other symptoms 
not resulting in a specific diagnosis – such as suspected 
angina pectoris – and estimated prognosis that influence 
treatment decisions could result in confounding by indication 
and overestimated HRs. Among MM patients, patients with 
bone marrow failure, renal failure, and elderly frail patients 
not appropriate for other treatment typically are treated with 
ESAs. These more fragile patients are generally at higher risk 
of any adverse event. If any residual confounding were pres-
ent, our results were probably overestimated for this group.
Conclusion
We found that ESA use was associated with stroke in MDS 
patients. Among MM patients, ESA treatment was associated 
with a higher risk of all cardiovascular events, although all 
CIs included equivalence. Identification of patients who will 
benefit most from ESA treatment, may be even combined 
with antithrombotic agents to prevent cardiovascular events, 
is an important goal for future research.
Acknowledgments
The study was supported by the Aarhus University Research 
Foundation, the Danish Cancer Society, and the Program for 
Clinical Research Infrastructure (PROCRIN) established 
by the Lundbeck Foundation and the Novo Nordisk Foun-
dation. MMS, TH, and FWD were supported by the FP7-
Health European Commission EpoCan grant (282551). The 
European Commission was not involved in the collection, 
interpretation, and analysis of the data, nor in the decision 
for writing and submitting this report for publication.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
88
.2
09
.3
3 
on
 2
2-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1378
horváth-Puhó et al
Author contributions
EH-P, MMS, TH, SCC, FWD, and HTS contributed to the 
research design, LP was involved in acquisition of the data, 
and EH-P analyzed the data. EH-P, MMS, TH, HF, FWD, 
OMD, and HTS discussed the interpretation of the data. MMS 
and EH-P drafted the manuscript. All authors contributed 
toward data analysis, drafting and revising the paper and 
agree to be accountable for all aspects of the work.
Disclosure
The authors report no conflict of interest in this work. 
References
 1. Glaspy J. Current status of use of erythropoietic agents in cancer 
patients. Semin Thromb Hemost. 2014;40(3):306–312.
 2. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human eryth-
ropoiesis-stimulating agents and mortality in patients with cancer: a 
meta-analysis of randomised trials. Lancet. 2009;373(9674):1532–1542.
 3. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human 
erythropoietin and overall survival in cancer patients: results of a com-
prehensive meta-analysis. J Natl Cancer Inst. 2005;97(7):489–498.
 4. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoi-
etins and cancer patients: updated meta-analysis of 57 studies including 
9353 patients. J Natl Cancer Inst. 2006;98(10):708–714.
 5. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating 
agents in oncology: a study-level meta-analysis of survival and other 
safety outcomes. Br J Cancer. 2010;102(2):301–315.
 6. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythro-
poiesis-stimulating agents in patients with chronic kidney disease. Ann 
Intern Med. 2010;153(1):23–33.
 7. Oster HS, Neumann D, Hoffman M, Mittelman M. Erythropoietin: the 
swinging pendulum. Leuk Res. 2012;36(8):939–944.
 8. Landolfi R, Di Gennaro L. Thrombosis in myeloproliferative and myelo-
dysplastic syndromes. Hematology. 2012;17(Suppl 1):S174–S176.
 9. Smith SW, Sato M, Gore SD, et al. Erythropoiesis-stimulating agents 
are not associated with increased risk of thrombosis in patients with 
myelodysplastic syndromes. Haematologica. 2012;97(1):15–20.
 10. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in 
patients with myelodysplastic syndrome receiving thalidomide in com-
bination with darbepoietin-alpha. Br J Haematol. 2003;121(1):101–103.
 11. Knight R, Delap RJ, Zeldis JB. Lenalidomide and venous thrombosis 
in multiple myeloma. N Engl J Med. 2006;354(19):2079–2080.
 12. Leleu X, Rodon P, Hulin C, et al. MELISSE, a large multicentric obser-
vational study to determine risk factors of venous thromboembolism in 
patients with multiple myeloma treated with immunomodulatory drugs. 
Thromb Haemost. 2013;110(4):844–851.
 13. Bennett CL, Spiegel DM, MacDougall IC, et al. A review of safety, 
efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide 
for patients with cancer or chronic kidney disease: a report from the 
Southern Network on Adverse Reactions (SONAR). Semin Thromb 
Hemost. 2012;38(8):783–796.
 14. Galli M, Elice F, Crippa C, Comotti B, Rodeghiero F, Barbui T. 
Recombinant human erythropoietin and the risk of thrombosis in 
patients receiving thalidomide for multiple myeloma. Haematologica. 
2004;89(9):1141–1142.
 15. Frank L. Epidemiology. When an entire country is a cohort. Science. 
2000;287(5462):2398–2399.
 16. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration 
System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549.
 17. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 
2011;39(7 Suppl):42–45.
 18. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, 
Sørensen HT. The Danish National Patient Registry: a review of content, 
data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
 19. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen 
L, Sørensen HT. Existing data sources for clinical epidemiology: The 
Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 
2012;4:303–313.
 20. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. 
Expert Rev Anticancer Ther. 2007;7(3):307–315.
 21. Falanga A, Marchetti M, Russo L. Venous thromboembolism in the 
hematologic malignancies. Curr Opin Oncol. 2012;24(6):702–710.
 22. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-
dose dexamethasone versus lenalidomide plus low-dose dexamethasone 
as initial therapy for newly diagnosed multiple myeloma: an open-label 
randomised controlled trial. Lancet Oncol. 2010;11(1):29–37.
 23. Anaissie EJ, Coleman EA, Goodwin JA, et al. Prophylactic recombinant 
erythropoietin therapy and thalidomide are predictors of venous throm-
boembolism in patients with multiple myeloma: limited effectiveness 
of thromboprophylaxis. Cancer. 2012;118(2):549–557.
 24. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A. Thromboembolic 
events with lenalidomide-based therapy for multiple myeloma. Cancer. 
2008;112(7):1522–1528.
 25. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of 
r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). 
Br J Haematol. 1995;89(4):831–837.
 26. Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration 
of erythropoietin increases erythroid response rate in myelodysplastic 
syndromes: a phase II trial in 281 patients. Br J Haematol. 2002;118(1): 
174–180.
 27. Yang X, Brandenburg NA, Freeman J, et al. Venous thromboembolism 
in myelodysplastic syndrome patients receiving lenalidomide: results 
from postmarketing surveillance and data mining techniques. Clin Drug 
Investig. 2009;29(3):161–171.
 28. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and 
venous thrombosis in monoclonal gammopathy of undetermined 
significance and multiple myeloma: a population-based study. Blood. 
2010;115(24):4991–4998.
 29. Malki N, Koupil I, Eloranta S, et al. Temporal trends in incidence of 
myocardial infarction and ischemic stroke by socioeconomic position 
in Sweden 1987-2010. PLoS One. 2014;9(8):e105279.
 30. van Oeffelen AA, Agyemang C, Stronks K, Bots ML, Vaartjes I. Inci-
dence of first acute myocardial infarction over time specific for age, 
sex, and country of birth. Neth J Med. 2014;72(1):20–27.
 31. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT. 25 year 
trends in first time hospitalisation for acute myocardial infarction, subse-
quent short and long term mortality, and the prognostic impact of sex and 
comorbidity: a Danish nationwide cohort study. BMJ. 2012;344:e356.
 32. Kissela BM, Khoury JC, Alwell K, et al. Age at stroke: temporal 
trends in stroke incidence in a large, biracial population. Neurology. 
2012;79(17):1781–1787.
 33. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects 
of erythropoietin. Cardiovasc Res. 2003;59(3):538–548.
 34. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red 
cell abnormalities. Semin Thromb Hemost. 2003;29(5):451–458.
 35. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythro-
poiesis-stimulating agents. Semin Thromb Hemost. 2010;36(5):537–549.
 36. Malyszko J, Malyszko JS, Borawski J, et al. A study of platelet functions, 
some hemostatic and fibrinolytic parameters in relation to serotonin 
in hemodialyzed patients under erythropoietin therapy. Thromb Res. 
1995;77(2):133–143.
 37. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Pro-
thrombotic effect of erythropoietin in dialysis patients. Nephrol Dial 
Transplant. 1992;7(3):235–239.
 38. Björk J, Albin M, Mauritzson N, Strömberg U, Johansson B, Hag-
mar L. Smoking and myelodysplastic syndromes. Epidemiology. 
2000;11(3):285–291.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
88
.2
09
.3
3 
on
 2
2-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1379
Esa and cardiovascular events in MM and MDs
 39. Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple 
myeloma (MM). Hematology. 2012;17(Suppl 1):S177–S180.
 40. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen 
HT. The predictive value of ICD-10 diagnostic coding used to assess 
Charlson comorbidity index conditions in the population-based Danish 
National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
 41. Sundbøll J, Adelborg K, Munch T, et al. Positive predictive value of 
cardiovascular diagnoses in the Danish National Patient Registry: a 
validation study. BMJ Open. 2016;6(11):e012832.
 42. Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled 
trials: a critical comparison of trials with nonrandomized studies. 
Hepatology. 2006;44(5):1075–1082.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
88
.2
09
.3
3 
on
 2
2-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk and safety of medical interventions, epidemiol-
ogy and biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies and economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Dovepress
1380
horváth-Puhó et al
Supplementary material
Table S1 iCD codes, treatment, and aTC codes used in the study.
Variables ICD-8 codes ICD-10 codes Treatment codes ATC codes
Study population
Multiple myeloma C90.0
Myelodysplastic syndrome D46
standard prognosis D46.0, D46.1, D46.6
Poor prognosis D46.2, D46.5
Other D46.4, D46.7, D46.9
Exposure
Erythropoiesis-stimulating agents BOhE10 B03Xa01, B03Xa02, B03Xa03
Outcomes
Venous thromboembolism 451.00, 450.99 i80.1, i80.2, i80.3, i26
Myocardial infarction 410 i21
stroke 431-434 i61, i63, i64
Covariates
Cardiovascular disease 393-398, 400-404, 
410-414, 427.09, 
427.10, 427.19
i05-i09, i10-i15, 
i20-i25, i50
C09, B01aC06, n02Ba01, 
C07, C08, C03, C01Da, 
C10aa, B04aB, C02
Chronic kidney disease 249.02, 250.02, 
582, 583, 584, 
590.09, 593.20, 
753.10-753.19, 792
E10.2, E11.2, E14.2, 
n03, n05, n11.0, 
n14; n16, n18-n19, 
n26.9, Q61.1-Q61.4
Diabetes mellitus 249-250 (except 
249.02 and 250.02)
E10-E11 (except 
E10.2 and E11.2), O24 
(except O24.4), h36.0
a10B, a10a
statin use C10aa
antithrombotic therapy BOha03 B01a
Chemotherapy BWha
radiation therapy BWg
immunomodulating and bone 
modulating therapy (interferon, 
retinoid, azathioprine, 
bisphosphonates)
BWhB
lenalidomide BWhB82 l04aX04
Thalidomide BWhB81 l04aX02
azacitidine BWha256
Filgrastim BOhE2
Thrombopoietin analogs BOhE4
Abbreviations: ATC, anatomical therapeutic chemical classification system; ICD, International Classification of Diseases.
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